文献速递临床试验与 GCP真实世界研究与卫生经济新药、器械与细胞基因治疗研发

逆转录病毒基因治疗腺苷脱氨酶缺乏症的长期真实世界安全性与疗效

Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.
PubMed 文献 · Nat Med · 2024-02-14

该研究报告43例腺苷脱氨酶缺乏所致重症联合免疫缺陷患者接受逆转录病毒体外骨髓来源造血干细胞基因治疗后的长期安全性与疗效数据,中位随访5.0年时全部存活,2年无干预生存率为88%(95%CI 78.7-98.4%),安全性特征与上市前队列一致,1例出现治疗相关T细胞白血病但已缓解,提示风险获益仍有利并需持续长期安全性监测。

要点

  • 43例腺苷脱氨酶缺乏所致重症联合免疫缺陷患者接受逆转录病毒体外骨髓来源造血干细胞基因治疗,中位随访5.0年时全部存活。
  • 2年无干预生存率为88%(95%CI 78.7-98.4%),无干预指无需长期酶替代治疗或异基因造血干细胞移植。
  • 1例名义患者计划中的患者于基因治疗后4.7年发生治疗相关T细胞白血病,目前处于缓解状态。

核心结论

  • 这些长期数据提示腺苷脱氨酶缺乏症基因治疗的风险获益仍有利,并需继续长期安全性监测。

研究设计与样本

  • 对43例接受逆转录病毒体外骨髓来源造血干细胞基因治疗的腺苷脱氨酶缺乏所致重症联合免疫缺陷患者进行长期安全性与疗效数据分析。
  • 22例在临床开发或名义患者计划背景下治疗,中位随访15.4年;19例在上市授权后治疗,中位随访3.2年;另2例接受动员外周血CD34+细胞基因治疗。

主要发现

  • 数据截止时43例患者全部存活,中位随访5.0年(四分位距2.4-15.4),2年无干预生存率为88%(95%CI 78.7-98.4%)。
  • 大多数不良事件/反应与疾病背景、白消安预处理或免疫重建相关,真实世界安全性特征与上市前队列一致。
  • 1例名义患者计划中的患者于基因治疗后4.7年发生治疗相关T细胞白血病,目前处于缓解状态。
  • 观察到多谱系基因校正细胞长期持续存在、代谢解毒、免疫重建和感染率下降。
  • 混合效应模型估计显示,输注CD34+细胞剂量较高和基因治疗时年龄较小对CD3+转导细胞、淋巴细胞和CD4+CD45RA+初始T细胞平台水平有正向影响,而细胞剂量对CD15+转导细胞最终平台水平有正向影响。

局限性

  • 需要进行长期数据验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Adenosine deaminase (ADA) deficiency leads to severe combined immunodeficiency (SCID). Previous clinical trials showed that autologous CD34+ cell gene therapy (GT) following busulfan reduced-intensity conditioning is a promising therapeutic approach for ADA-SCID, but long-term data are warranted. Here we report an analysis on long-term safety and efficacy data of 43 patients with ADA-SCID who received retroviral ex vivo bone marrow-derived hematopoietic stem cell GT. Twenty-two individuals (median follow-up 15.4 years) were treated in the context of clinical development or named patient program. Nineteen patients were treated post-marketing authorization (median follow-up 3.2 years), and two additional patients received mobilized peripheral blood CD34+ cell GT. At data cutoff, all 43 patients were alive, with a median follow-up of 5.0 years (interquartile range 2.4-15.4) and 2 years intervention-free survival (no need for long-term enzyme replacement therapy or allogeneic hematopoietic stem cell transplantation) of 88% (95% confidence interval 78.7-98.4%). Most adverse events/reactions were related to disease background, busulfan conditioning or immune reconstitution; the safety profile of the real world experience was in line with premarketing cohort. One patient from the named patient program developed a T cell leukemia related to treatment 4.7 years after GT and is currently in remission. Long-term persistence of multilineage gene-corrected cells, metabolic detoxification, immune reconstitution and decreased infection rates were observed. Estimated mixed-effects models showed that higher dose of CD34+ cells infused and younger age at GT affected positively the plateau of CD3+ transduced cells, lymphocytes and CD4+ CD45RA+ naive T cells, whereas the cell dose positively influenced the final plateau of CD15+ transduced cells. These long-term data suggest that the risk-benefit of GT in ADA remains favorable and warrant for continuing long-term safety monitoring. Clinical trial registration: NCT00598481 , NCT03478670 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Migliavacca M, Barzaghi F, Fossati C, et al. Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nat Med. 2024. PMID: 38355973. doi:10.1038/s41591-023-02789-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。